Hyaluronan modulates accumulation of hypoxia-inducible factor-1 alpha, inducible nitric oxide synthase, and matrix metalloproteinase-3 in the synovium of rat adjuvant-induced arthritis model
© Chou et al.; licensee BioMed Central Ltd. 2011
Received: 10 February 2011
Accepted: 16 June 2011
Published: 16 June 2011
Hypoxia is a feature of the inflamed synovium in rheumatoid arthritis (RA). Intra-articular injection of hyaluronan (HA) may be considered a potential way to treat RA. However, the exact molecular mechanism of HA on decreased cellular responses to hypoxic environment is unclear. The present study has been designed to use the adjuvant-induced arthritis model to examine the effects of HA on the changes of immunohistochemical expressions of hypoxia-inducible factor-1alpha (HIF-1alpha), inducible nitric oxide synthase (iNOS), and matrix metalloproteinase-3 (MMP3) in the synovial tissues at the early phase of arthritic inflammation.
Monoarthritis was induced in adult male Sprague-Dawley (250-300 g) via intraarticular injection of complete Freund's adjuvant (CFA) into the tibiotarsal joint. The CFA-induction arthritis animals were divided into three groups: treatment (intraarticular injection of HA), placebo (intraarticular injection of saline) and controls (no treatments). Functional evaluations of edema and pain behavior, histology, and HIF-1alpha, iNOS, and MMP3 immunohistochemistry were performed before, after the first injection, three injections, and on the follow-up injection of the treatments.
Intra-articular injection of HA also significantly suppressed the mechanical allodynia (p < 0.001) and overexpressions of HIF-1alpha (p < 0.001), iNOS (p = 0.004) and MMP3 (p < 0.001) immunoreactivity in synovium.
This study demonstrated that early intervention of HA is an effective protection against accumulation of inflammation-induced HIF-1alpha, iNOS, and MMP3 to limit erosive damage in CFA-induced model of arthritis.
A hypoxic microenvironment is a hallmark of the inflamed synovium and its importance in the pathogenesis of rheumatoid arthritis (RA) has been documented [1–4]. In human and animal arthritis models, the importance of hypoxia for the development and persistence of RA has been demonstrated [1, 5]. Previous studies have demonstrated the hypoxic nature of the synovium of patients with RA and the constitutive expression of hypoxia-inducible factor-1-alpha (HIF-1α), a key regulator of hypoxia transcriptional response. In RA joints hypoxia has been shown to express increased amounts of HIF-1α and HIF-1 target genes in synovial lining cells and articular chondrocytes under hypoxic conditions, which aggravate joint inflammation [6, 7]. Previous studies also demonstrated that hypoxia takes place in the synovium at the pre-arthritic stage or early stage of the disease and has a close spatial relationship and positive severity correlation with synovitis . Therefore, HIF-1α is identified as a key player in the pathogenesis of RA and a potential therapeutic target in RA development.
Nitric oxide (NO) synthesized from arginine by nitric oxide synthases (NOS) is an important chemical mediator of inflammation. The inducible isoform of NOS (iNOS) is primarily responsible for producing large amounts of NO and its overexpression has been linked to the progressive inflammation and tissue destruction observed in hypoxic experimental arthritis [9, 10] and human rheumatoid synovium [11, 12]. Matrix metalloproteinases (MMPs), the most important matrix-degrading enzymes in RA, act as key mediators of the resorption of cartilage, bone, synovial fluid, and adjacent soft tissue, and this resorption occurs as part of the pathological destruction of joint tissue . Among dozens of MMPs, MMP3 (stromelysin 1) has been reported to be the major enzyme produced by fibroblasts and macrophage-like cells in the synovium, and the level of MMP3 has been reported to be significantly higher in synovial fluids from patients with RA [14–16]. Under the inflammatory conditions of RA, the levels of HIF-1α, iNOS, and MMP3 are significantly higher in synovial fluids in previous studies and thus are implicated in the pathogenesis of RA. Expressions of iNOS and MMP3 are probably regulated by HIF-1α in the cellular response to hypoxic and inflammatory environments [11, 17, 18]. Therefore, inhibition or downregulation of these molecules (or both) may exert anti-hypoxic and anti-inflammatory effects.
Hyaluronan (HA) is a polymer of disaccharides and has a high capacity for holding water and possesses high viscoelasticity . The intra-articular supplementation of HA can replace synovial fluid, which has lost its viscoelastic properties. HA has been widely used for the treatment of osteoarthritis (OA) . HA not only is a lubricating agent but its exogenous administration can suppress the expression of inflammatory cytokines, MMPs, and free oxygen radicals to reduce inflammation in a post-laminectomy rat model  and patients with RA . Therefore, it has been expected that the intra-articular injection of HA is more efficacious in treating RA, which principally characterizes articular synovitis [21, 22]. However, for RA joint treatment, the clinical use of HA is still rare because its immunoregulatory action is still debatable.
Complete Freund's adjuvant (CFA)-induced arthritis shares some characteristics of RA. This model mirrors much of the pathology of RA, including hyperplasia of the synovial tissues, inflammatory infiltration of the joints, and destruction of bone and cartilage in the synovial joint . The present study has been designed to use the adjuvant-induced arthritis model to examine the effects of HA on the changes of immunohistochemical expressions of HIF-1α, iNOS, and MMP3 in the synovial tissues in the early phase of arthritic inflammation. We hypothesize that the addition of HA will alleviate inflammatory nociception and impede the accumulation of arthritis-induced HIF-1α, iNOS, and MMP3 production in the early phase of the experimental arthritic inflammatory joint. This hypothesis, if correct, will offer at least a partial explanation for the efficacy of topical HA application in the subsequent inhibition of hypoxic inflammation in this preclinical model.
Materials and methods
Ninety adult male Sprague-Dawley (SD; purchased from BioLASCO Taiwan Co., Ltd., Taiwan, Republic of China) rats weighing 250 to 300 g were kept in the Laboratory Animal Center of China Medical University. An effort was made to minimize discomfort and to reduce the number of animals used. All animal experiments were conducted with the approval of the Animal Care and Use Committee of China Medical University in accordance with the Guidelines for Animal Experimentation.
Induction of monoarthritis
Monoarthritis was induced by an injection of CFA into the unilateral ankle articular cavity. The rats were briefly anesthetized with 4% isoflurane (AERRANE; Baxter Healthcare Corporation, San Juan, Puerto Rico). A 28-gauge needle was vertically inserted distally into the articular cavity from the gap between the tibiofibular and tarsus bone. CFA with a volume of 50 μL (10 mg of mycobacterium, F5881; Sigma-Aldrich, St. Louis, MO, USA) was then injected. The monoarthritic animals were placed separately in clear acrylic containers (10.5-inch width × 19-inch diameter × 8-inch height), and free movement was allowed for at least 24 hours to let the animals adjust to these conditions before any experimentation was performed.
Ultrasound-guided hyaluronan injection
While the animals were under brief isoflurane anesthesia, ultrasound (Terason t3000™ Ultrasound System; Terason Division, Teratech Corporation, Burlington, MA, USA)-guided injection was performed on the lateral side of the tibiotarsal joint, and the transducer in the sagittal plane showed the distal end of the tibia and proximal part of the tarsus in the image plane. Needle insertion was performed perpendicularly to the transducer. HA injection (molecular weight of 1.2 to 1.4 × 106 Da; Ostenil®, 10 mg/mL sodium hyaluronate; TRB Chemedica AG, München, Germany) was documented by recording an image clip during injection with the needle tip in the image plane.
Pain threshold assessment
The pain thresholds were determined by nociceptive thresholds to mechanical stimulation. The test consisted of evoking a hind paw flexion reflex with a handheld force transducer (electronic von Frey anesthesiometer; IITC Inc., Woodland Hills, CA, USA) adapted with a 0.5 mm2 polypropylene tip. In a quiet room, the rats were placed in acrylic cages (32 × 22 × 27 cm high) with a wire grid floor for 15 to 30 minutes of habituation prior to testing. The polypropylene tip was applied perpendicularly to the central area of the hind paw with sufficient force to bend the filaments into an 'S' shape for 3 to 4 seconds. The test consisted of poking a hind paw to provoke a flexion reflex followed by a clear flinch response after paw withdrawal. Testing was initiated with the filament corresponding to 20 log of force (g). The filaments were applied with a gradual increase in pressure until a withdrawal reflex response was finally detected from the animal. The response to this filament is defined if a series of weaker or stronger filaments would be tested. The weakest filament able to elicit a response was taken to be the paw withdrawal threshold (g). The intensity of the pressure was recorded, and the final value for the response was obtained by averaging five measurements.
Measurement of edematous swelling of the paw
The extent of peripheral swelling was assessed by measuring the circumference of the paw at intact and CFA-injected sites with a flexible tape. The paw circumference was obtained by averaging three measurements. The difference in the ankle circumference between the initial value (pre-arthritic data) and that at each time point after injection is expressed as change (percentage) = 100% × [(post-arthritic circumference)-(pre-arthritic circumference)]/(pre-arthritic circumference). All assessments, including paw withdrawal and swelling measurements, were performed with the assessor blinded with respect to treatment.
Histology and immunohistochemistry
Animals were killed by anesthetic overdose after treatments of 1D (n = 10 for each group), 3D (n = 10 for each group), and 3D6d (n = 10 for each group) on days 2, 6, and 12. Hind ankles were collected for histological and immunohistological analysis. The formalin-fixed, paraffin-embedded joint tissues (including synovium and cartilage tissues) were cut at a thickness of 5 μm for histology and immunohistochemistry. Histological confirmation of the arthritic pathology was performed with hematoxylin and eosin-stained sections. Sections were deparaffinized in 200 mL of Trilogy (Cell Marque Corporation, Rocklin, CA, USA) and incubated with 3% H2O2 in methanol for 20 minutes at room temperature. Subsequently, sections were treated with proteinase K (Sigma-Aldrich) at 0.1 mg/mL for 20 minutes at room temperature to unmask epitopes and this was followed by phosphate-buffered saline (PBS) rinse. Sections were incubated with blocking buffer (Power Block™; Biogenex, Fremont, CA, USA) for 2 hours at room temperature followed by incubation overnight at 4°C with the mouse monoclonal antibody anti-HIF-1α (diluted 1:100; Thermo, Fremont, CA, USA) and with the following rabbit polyclonal antibodies: anti-iNOS (diluted 1:200; Thermo) and anti-MMP3 (diluted 1:200; Abbiotec, San Diego, CA, USA). After three washes with PBS containing 0.05% Tween-20 for 10 minutes, sections were incubated with biotinylated anti-rabbit and anti-mouse immunoglobulins (Jackson ImmunoResearch Laboratories, Inc., West Grove, PA, USA) followed by a 30-minute peroxidase-conjugated streptavidin incubation (Jackson ImmunoResearch Laboratories, Inc.). Sections were incubated with 3,3'-diaminobenzidine (Biogenex), dehydrated, and cover-slipped with Permount (Sigma-Aldrich, St. Louis, MO, USA). Negative controls were performed by substituting the primary antibody with non-immune serum.
The histopathology of synovium was analyzed by the non-parametric scoring system described by Smith and colleagues . The scores ranged from 0 to 3 for each of the tissue criteria, including intimal hyperplasia, lymphocytic infiltration, subintimal fibrosis, and vascularity. The higher aggregate score was considered to reflect increased pathological changes. Five randomly selected sections were scored and repeated two times for statistical analysis. Quantitative analysis of immunostainings was carried out by light microscopy in synovial tissue lining the joint cavity and synovial tissue attached to the cartilage. The number of HIF-1α, iNOS, and MMP3 immunoreactive cells was counted among at least five alternate sections in the more representative fields by using a microscope. Positive nuclei and cytoplasm staining cells for HIF-1α, iNOS, and MMP3 were counted in high-power fields (× 200 magnification) that contained synovial lining cells. The area sizes of high-power fields were calculated by using a stage micrometer (with 100 gradations of 0.01 mm each) when viewed using a × 200 objective. Ten fields of each slide were counted for all samples and repeated three times for statistical analysis. Results were expressed as the proportion (percentage) of labeled cells per square millimeter of synovium. For statistical analysis, the mean value obtained from the repeated counts was used. All of the scoring and quantitative analyses were assessed by two independent observers who were blinded to the origin of the sections to avoid bias from interobserver variability.
The differences of value in each assessment between pre- and post-arthritic evaluations were analyzed by Student t test. The differences among the HA, SA, and No-tr groups on each dosage (1D, 3D, and 3D6d) were analyzed using analysis of variance and later were analyzed further by a Bonferroni post hoc method. Similar statistical analysis methods were used to test the differences among dosages in each group. Non-parametric data (histological synovial scoring) were analyzed using the Kruskal-Wallis test for multiple groups and Mann-Whitney U tests for between-group comparisons. The Pearson correlation test was applied to study the correlations between pain withdrawal threshold and expressions of immunoreactivities. A P value of less than 0.05 was considered statistically significant. All data were analyzed using SPSS version 10.0 for Windows (SPSS Inc., Chicago, IL, USA).
Effect of hyaluronan on complete Freund's adjuvant-induced edema
After treatment, the significant time-dependent differences in edema development were observed in each group (HA group: P < 0.001; SA group: P < 0.001; and No-tr group: P < 0.001). However, there was no difference in the edema of arthritic paws among the HA, SA, and No-tr groups after treatments of 1D (P = 0.22), 3D (P = 0.41), and 3D6d (P = 0.31). Therefore, intra-articular injections of HA, regardless of different dosages for 1D, 3D, and 3D6d, did not ameliorate joint swelling compared with either the SA or the No-tr group.
Effect of hyaluronan on complete Freund's adjuvant-induced inflammatory mechanical nociception
The serial alterations of the paw withdrawal threshold (mean ± SEM) throughout the whole experiment for each group are shown in Figure 2B. The mean threshold was 25.07 ± 4.68 g at pre-arthritic conditions. However, after CFA induction, it decreased to 9.32 ± 3.16 g. There was a significant difference with pre-arthritic conditions (P < 0.001).
The significant differences in paw withdrawal threshold were shown among the HA, SA, and No-tr groups after treatment of 1D (P = 0.008), 3D (P < 0.001), and 3D6d (P < 0.001). A significantly lower threshold existed after treatment of 1D, 3D, and 3D6d in the SA and No-tr groups compared with those in the HA group (HA versus SA, P = 0.04; HA versus No-tr, P = 0.01 for 1D; HA versus SA, P < 0.001; HA versus No-tr, P < 0.001 for 3D; HA versus SA, P < 0.001; HA versus No-tr, P = 0.001 for 3D6d). The analysis also showed that there was a significantly lower threshold in the No-tr group compared with the SA group after treatment of 3D (P = 0.03) and 3D6d (P = 0.01). However, no significant difference was observed between these groups after treatment of 1D (P = 1.0).
There were significant differences among three dosages in the HA group (P < 0.001) but not in the SA (P = 0.84) and No-tr (P = 0.56) groups. After HA treatment, the paw withdrawal threshold showed a significant increase in 3D and 3D6d treatments compared with 1D treatment (1D versus 3D, P < 0.001; 1D versus 3D6d, P < 0.001). However, no difference was observed between the 3D and 3D6d of HA treatments (P = 0.05).
Results of histopathological scores of synovium for sections in arthritic ankle joint sampled from three treatment groups
2.45 ± 0.11
2.60 ± 0.11
1.50 ± 0.11a, b
2.05 ± 0.11
7.80 ± 0.26a, b
2.60 ± 0.11
2.60 ± 0.11
2.50 ± 0.11
2.10 ± 0.12
9.10 ± 0.31
2.65 ± 0.11
2.65 ± 0.10
2.95 ± 0.05
2.20 ± 0.12
9.75 ± 0.24
cP value among groups
P > 0.05
P > 0.05
P > 0.05
2.50 ± 0.11
2.70 ± 0.11
1.40 ± 0.13a, b
2.20 ± 0.09
8.05 ± 0.31a, b
2.80 ± 0.09
2.70 ± 0.10
2.55 ± 0.11
2.15 ± 0.11
9.55 ± 0.28
2.80 ± 0.09
2.70 ± 0.11
2.85 ± 0.08
2.20 ± 0.14
9.95 ± 0.32
cP value among groups
P > 0.05
P > 0.05
P > 0.05
2.50 ± 0.11
2.50 ± 0.11
1.40 ± 0.11a, b
2.15 ± 0.11
7.85 ± 0.25a, b
2.70 ± 0.11
2.60 ± 0.10
2.77 ± 0.10
2.20 ± 0.14
9.6 ± 0.36
2.70 ± 0.11
2.70 ± 0.11
2.85 ± 0.08
2.40 ± 0.11
10.05 ± 0.33
Immunohistochemical assessments on location of HIF-1α, iNOS, and MMP3
Quantitative analysis of extent of HIF-1α, iNOS, and MMP3 immunoreactive expressions
After treatment, the significant differences in extent of HIF-1α, iNOS, and MMP3 immunoreactive expressions were shown among the HA, SA, and No-tr groups after treatment of 1D (HIF-1α: P < 0.001; iNOS: P < 0.001; MMP3: P < 0.001), 3D (HIF-1α: P < 0.001; iNOS: P < 0.001; MMP3: P < 0.001), and 3D6d (HIF-1α: P < 0.001; iNOS: P < 0.001; MMP3: P < 0.001). Significantly lower expressions of HIF-1α, iNOS, and MMP3 immunoreactivities existed after treatment of 1D in the HA group-HIF-1α: HA versus SA, P < 0.001; HA versus No-tr, P < 0.001 (Figure 4D); iNOS: HA versus SA, P < 0.001; HA versus No-tr, P < 0.001 (Figure 5D); MMP3: HA versus SA, P < 0.001; HA versus No-tr, P < 0.001 (Figure 6D). The analysis also showed that there were no significant differences in HIF-1α, iNOS, and MMP3 immunoreactivities between the SA and No-tr groups for 1D dosage (HIF-1α: SA versus No-tr, P = 0.14; iNOS: P = 0.45; MMP3: P = 1.0) (Figures 4D, 5D, and 6D). Similar results were found for HIF-1α, iNOS, and MMP3 immunoreactivities for treatments of 3D and 3D6d (Figures 4D, 5D, and 6D).
Significant differences in extent of HIF-1α, iNOS, and MMP3 immunoreactive expressions were shown among 1D, 3D, and 3D6d dosages in the HA group (HIF-1α: P < 0.001; iNOS: P = 0.004; MMP3: P < 0.001) but not in the SA group (HIF-1α: P = 0.56; iNOS: P = 0.85; MMP3: P = 0.81) or the No-tr group (HIF-1α: P = 0.16; iNOS: P = 0.50; MMP3: P = 0.99). After 3D and 3D6d of HA treatment, the extent of HIF-1α and iNOS immunoreactive expressions significantly reached maximum reduction compared with those of 1D treatment-HIF-1α: 3D versus 1D, P < 0.001; 3D6d versus 1D, P = 0.03 (Figure 4D); iNOS: 3D versus 1D, P = 0.01; 3D6d versus 1D, P = 0.03 (Figure 5D). However, no difference was exhibited between the 3D and 3D6d of HA treatments (HIF-1α: 3D versus 3D6d, P = 0.15; iNOS: 3D versus 3D6d, P = 1.0). For expression of MMP3 immunoreactivity, significant reduction was found after 3D treatment (3D versus 1D, P = 0.001; 3D versus 3D6d, P < 0.001) (Figure 6D). However, the expression of MMP3 immunoreactivity recovered after 3D6d treatment (3D6d versus 1D, P = 1.0).
Association of pain withdrawal threshold with immunoreactivity results
Association of pain withdrawal threshold with the immunoreactivity results given as gamma values
Pain withdrawal threshold
The results of this study demonstrate that lymphocytic/plasmocytic infiltration in the synovium and accumulation of HIF-1α, iNOS, and MMP3 were suppressed after intra-articular administration of HA at the early phase of adjuvant-induced inflammation. The extent of HIF-1α, iNOS, and MMP3 immunoreactivities was consistent with the results of pain behavioral assessment, which demonstrated an elevation of the mechanonociceptive threshold after administration of HA. To the best of our knowledge, these findings have never been reported by other researchers.
In this model, the early phases of adjuvant-induced arthritis seem to be characterized by acute cytokine-induced inflammation . Owing to infiltration of the injured tissues by immune cells and responses, swelling is a major sign during acute inflammation and might also be considered an important parameter on evaluation of the potential anti-inflammatory effects of compounds . However, as shown in the results of our study, the levels of edematous swelling were not changed after HA treatment in acute inflammation at the early phase of adjuvant-induced arthritis, suggesting the weaker activity against edema of HA in an acute inflammatory animal model. This result is consistent with the animal study with collagen-induced arthritis  and human study with OA . The reason is probably due to a HA-induced swelling adverse effect at the injection site occurring. Previous studies revealed that HA may act as either a primary irritant or an inflammatory mediator to induce acute adverse events characterized by transient swelling of the injected joint in some patients [28–30]. The prevalence of adverse effects was noted in 47% of patients after HA supplementation and in 22% of patients treated with saline injections . In this study, the observation time of edema measurement started 3 hours after HA administration, when an adverse effect of a transient increase in swelling at the injection site occurred. Therefore, further study with long-term observations of joint swelling after ceasing HA was needed to clarify the effect of exogenous HA on resolving RA-induced joint edema.
It has been well established by animal behavioral and human clinical studies that elastoviscous solutions of HA could have an analgesic effect when injected into arthritic joints and if appropriately applied to patients with acute arthritic pain . There was significantly less bradykinin found in the crystal-induced arthritic joint after injection of HA . Electrophysiological studies also demonstrated that the rates of neural discharges of the nociceptive afferent fibers innervating the synovial tissue were significantly attenuated and reached a constant rate 2 to 3 hours after injection [32, 34, 35]. Treatment of HA showed an analgesic effect after the onset of cartilage destruction and pain in a rabbit OA model . To the best of our knowledge, our behavioral study is the first report on the analgesic effect of HA at decreased mechanical allodynia in a rat RA model and is consistent with the findings of previous studies. The intra-articular injection of HA also resulted in elevation of the mechanonociceptive threshold, which was in accordance with the results of immunohistochemistry in this study. HA has been demonstrated to possess a therapeutic effect on OA and this effect has been studied by many researchers. Macroscopic and microscopic evaluations revealed that HA has chondroprotective effects in a rabbit model of OA . Our results showed that HA reduced pathohistological signs, including the degree of infiltration of the synovial membrane by plasma and lymphocytes, in collagen-induced arthritis animals, and are consistent with findings from a previous study . The tendency for decreased cellular infiltration during the early phase of arthritis supports the assumption that HA provides a temporary protective barrier over the cartilage and thereby protects it against CFA insults. HA has also been shown to significantly suppress NO production and inhibit IL-1β-induced MMP3 production from OA synovial tissue in vitro and in vivo [39–42]. As far as we know, few English language studies of the role of HA on suppression of HIF-1α-mediated hypoxic and inflammatory responses have been conducted in OA models. Owing to less inflammation in OA synovial tissue, there is minor HIF-1α expression in these tissues . However, there is higher expression of HIF-1α immunohistochemistry in RA synovial tissues compared with OA tissues because the latter tissue, by nature, is inflammatory and angiogenic in RA . Therefore, HIF-1α has the potential to serve as an anti-rheumatic drug activity biomarker in the clinic and is expected to significantly affect/accelerate the clinical development of treatment for RA.
The possible important role of HIF-1α in RA has been extensively discussed [43, 44]. The presence of both hypoxia and inflammatory proteins in RA synovium, which both lead to HIF-1α stabilization and subsequent HIF-1 activation, seems to highlight the important role of HIF-1α . Elevated synovial angiogenesis is a key event during the course of RA. The modulation and blockade of angiogenesis via drug interventions have been shown to contribute to therapeutic efficacy in rat models of arthritis . HIF-1α probably has a crucial involvement in the angiogenic process of synovium in RA by regulation of its target gene, vascular endothelial growth factor (VEGF) . Inhibition of HIF-1α protein expression and VEGF production by SMP-114, a disease-modifying anti-rheumatic drug, has been shown to be of therapeutic benefit in RA . Oral administration of the inhibitor of heat shock protein 90 (Hsp90), which has been shown to potently reduce HIF-1α-related signaling and VEGF production, has also been found to decrease inflammation and cartilage damage in in vivo models of RA . Therefore, suppression of HIF-1α may have key implications in the development of novel therapeutic strategies revolutionizing the treatment of RA. Results showed that HA suppressed the adjuvant-induced overexpression of iNOS and MMP3, and this is consistent with findings from previous studies. To the best of our knowledge, our study is the first to report that HA suppresses HIF-1α. This study revealed the reduction of accumulation of HIF-1α expression in the synovium of an adjuvant-induced RA model after intra-articular HA administration. The suppressive effects on accumulation of inflammation-induced HIF-1α, iNOS, and MMP3 expressions in the synovium may be involved in the therapeutic mechanism of HA intervention used in the treatment of RA. Further molecular studies on expressions of VEGF will be needed to fully support the issue of anti-angiogenic effects of HA.
Suppression of HIF-1α may be one of the major targets of the therapeutic approach in RA. This study demonstrated that early intervention of HA is an effective protection against accumulation of inflammation-induced HIF-1α, iNOS, and MMP3 and might limit the erosive joint damage of arthritis. The findings suggest that modulation of HIF-1α as a 'master switch' may be used as a therapeutic target in the anti-inflammatory treatment of RA.
follow-up at the sixth day after three doses
complete Freund's adjuvant
inducible nitric oxide synthase
nitric oxide synthases
standard error of the mean
vascular endothelial growth factor.
The authors gratefully acknowledge the technical expertise of Shih-Chung Chen in counting immunohistochemical-labeled cells and Pin-Wen Tu in recording data of the animals' functional evaluations. This work was supported by a grant from China Medical University and Hospital (grants CMU-98-S-10 to Y-LH and DMR-96-073 to L-WC).
- Peters CL, Morris CJ, Mapp PI, Blake DR, Lewis CE, Winrow VR: The transcription factors hypoxia-inducible factor 1alpha and Ets-1 colocalize in the hypoxic synovium of inflamed joints in adjuvant-induced arthritis. Arthritis Rheum. 2004, 50: 291-296. 10.1002/art.11473.View ArticlePubMedGoogle Scholar
- Boyd HK, Lappin TR, Bell AL: Evidence for impaired erythropoietin response to anaemia in rheumatoid disease. Br J Rheumatol. 1991, 30: 255-259. 10.1093/rheumatology/30.4.255.View ArticlePubMedGoogle Scholar
- Oliver KM, Taylor CT, Cummins EP: Hypoxia. Regulation of NFkappaB signalling during inflammation: the role of hydroxylases. Arthritis Res Ther. 2009, 11: 215-10.1186/ar2575.View ArticlePubMedGoogle Scholar
- Paleolog EM: Angiogenesis in rheumatoid arthritis. Arthritis Res. 2002, 4 (Suppl 3): S81-S90. 10.1186/ar575.View ArticlePubMedGoogle Scholar
- Brouwer E, Gouw AS, Posthumus MD, van Leeuwen MA, Boerboom AL, Bijzet J, Bos R, Limburg PC, Kallenberg CG, Westra J: Hypoxia inducible factor-1-alpha (HIF-1alpha) is related to both angiogenesis and inflammation in rheumatoid arthritis. Clin Exp Rheumatol. 2009, 27: 945-951.PubMedGoogle Scholar
- Giatromanolaki A, Sivridis E, Maltezos E, Athanassou N, Papazoglou D, Gatter KC, Harris AL, Koukourakis MI: Upregulated hypoxia inducible factor-1alpha and -2alpha pathway in rheumatoid arthritis and osteoarthritis. Arthritis Res Ther. 2003, 5: R193-201. 10.1186/ar756.View ArticlePubMedGoogle Scholar
- Hollander AP, Corke KP, Freemont AJ, Lewis CE: Expression of hypoxia-inducible factor 1alpha by macrophages in the rheumatoid synovium: implications for targeting of therapeutic genes to the inflamed joint. Arthritis Rheum. 2001, 44: 1540-1544. 10.1002/1529-0131(200107)44:7<1540::AID-ART277>3.0.CO;2-7.View ArticlePubMedGoogle Scholar
- Jeon CH, Ahn JK, Chai JY, Kim HJ, Bae EK, Park SH, Cho EY, Cha HS, Ahn KS, Koh EM: Hypoxia appears at pre-arthritic stage and shows co-localization with early synovial inflammation in collagen induced arthritis. Clin Exp Rheumatol. 2008, 26: 646-648.PubMedGoogle Scholar
- Oyanagui Y: Nitric oxide and superoxide radical are involved in both initiation and development of adjuvant arthritis in rats. Life Sci. 1994, 54: PL285-289. 10.1016/0024-3205(94)00858-2.View ArticlePubMedGoogle Scholar
- Hashimoto K, Fukuda K, Yamazaki K, Yamamoto N, Matsushita T, Hayakawa S, Munakata H, Hamanishi C: Hypoxia-induced hyaluronan synthesis by articular chondrocytes: the role of nitric oxide. Inflamm Res. 2006, 55: 72-77. 10.1007/s00011-005-0012-6.View ArticlePubMedGoogle Scholar
- Ahn JK, Koh EM, Cha HS, Lee YS, Kim J, Bae EK, Ahn KS: Role of hypoxia-inducible factor-1alpha in hypoxia-induced expressions of IL-8, MMP-1 and MMP-3 in rheumatoid fibroblast-like synoviocytes. Rheumatology (Oxford). 2008, 47: 834-839. 10.1093/rheumatology/ken086.View ArticleGoogle Scholar
- Farrell AJ, Blake DR, Palmer RM, Moncada S: Increased concentrations of nitrite in synovial fluid and serum samples suggest increased nitric oxide synthesis in rheumatic diseases. Ann Rheum Dis. 1992, 51: 1219-1222. 10.1136/ard.51.11.1219.View ArticlePubMedGoogle Scholar
- Cawston T: Matrix metalloproteinases and TIMPs: properties and implications for the rheumatic diseases. Mol Med Today. 1998, 4: 130-137. 10.1016/S1357-4310(97)01192-1.View ArticlePubMedGoogle Scholar
- Tetlow LC, Wolley DE: Comparative immuno-localization studies of collagenase-1 and collagenase 3 production in the rheumatoid lesion, and by human chondrocytes and synoviocytes in vitro. Br J Rheumatol. 1998, 37: 64-70. 10.1093/rheumatology/37.1.64.View ArticlePubMedGoogle Scholar
- Yoshihara Y, Nakamura H, Obata K, Yamada H, Hayakawa T, Fujikawa K, Okada Y: Matrix metalloproteinases and tissue inhibitors of metalloproteinases in synovial fluids from patients with rheumatoid arthritis or osteoarthritis. Ann Rheum Dis. 2000, 59: 455-461. 10.1136/ard.59.6.455.View ArticlePubMedGoogle Scholar
- Keyszer G, Lambiri I, Nagel R, Keysser C, Keysser M, Gromnica-Ihle E, Franz J, Burmester GR, Jung K: Circulating levels of matrix metalloproteinases MMP-3 and MMP-1, tissue inhibitor of metalloproteinases 1 (TIMP-1), and MMP-1/TIMP-1 complex in rheumatic disease. Correlation with clinical activity of rheumatoid arthritis versus other surrogate markers. J Rheumatol. 1999, 26: 251-258.PubMedGoogle Scholar
- Fraisl P, Aragones J, Carmeliet P: Inhibition of oxygen sensors as a therapeutic strategy for ischaemic and inflammatory disease. Nat Rev Drug Discov. 2009, 8: 139-152. 10.1038/nrd2761.View ArticlePubMedGoogle Scholar
- Chen W, Ostrowski RP, Obenaus A, Zhang JH: Prodeath or prosurvival: two facets of hypoxia inducible factor-1 in perinatal brain injury. Exp Neurol. 2009, 216: 7-15. 10.1016/j.expneurol.2008.10.016.View ArticlePubMedGoogle Scholar
- Miltner O, Schneider U, Siebert CH, Niedhart C, Niethard FU: Efficacy of intraarticular hyaluronic acid in patients with osteoarthritis-a prospective clinical trial. Osteoarthritis Cartilage. 2002, 10: 680-686. 10.1053/joca.2002.0815.View ArticlePubMedGoogle Scholar
- Schimizzi AL, Massie JB, Murphy M, Perry A, Kim CW, Garfin SR, Akeson WH: High-molecular-weight hyaluronan inhibits macrophage proliferation and cytokine release in the early wound of a preclinical postlaminectomy rat model. Spine J. 2006, 6: 550-556. 10.1016/j.spinee.2005.12.005.View ArticlePubMedGoogle Scholar
- Saito S, Momohara S, Taniguchi A, Yamanaka H: The intra-articular efficacy of hyaluronate injections in the treatment of rheumatoid arthritis. Mod Rheumatol. 2009, 19: 643-651. 10.1007/s10165-009-0207-8.View ArticlePubMedGoogle Scholar
- Oliveira PG, Brenol CV, Edelweiss MI, Brenol JC, Petronilho F, Roesler R, Dal-Pizzol F, Schwartsmann G, Xavier RM: Effects of an antagonist of the bombesin/gastrin-releasing peptide receptor on complete Freund's adjuvant-induced arthritis in rats. Peptides. 2008, 29: 1726-1731. 10.1016/j.peptides.2008.05.031.View ArticlePubMedGoogle Scholar
- Brauer R, Kittlick PD, Thoss K, Henzgen S: Different immunological mechanisms contribute to cartilage destruction in antigen-induced arthritis. Exp Toxicol Pathol. 1994, 46: 383-388.View ArticlePubMedGoogle Scholar
- Smith MM, Cake MA, Ghosh P, Schiavinato A, Read RA, Little CB: Significant synovial pathology in a meniscectomy model of osteoarthritis: modification by intra-articular hyaluronan therapy. Rheumatology (Oxford). 2008, 47: 1172-1178. 10.1093/rheumatology/ken219.View ArticleGoogle Scholar
- Ferraccioli G, Bracci-Laudiero L, Alivernini S, Gremese E, Tolusso B, De Benedetti F: Interleukin-1beta and Interleukin-6 in arthritis animal models. Roles in the early phase of transition from the acute to chronic inflammation and relevance for human rheumatoid arthritis. Mol Med. 2010, 16: 552-557.View ArticlePubMedGoogle Scholar
- Morris CJ: Carrageenan-induced paw edema in the rat and mouse. Methods Mol Biol. 2003, 225: 115-121.PubMedGoogle Scholar
- Campo GM, Avenoso A, Campo S, Ferlazzo AM, Altavilla D, Calatroni A: Efficacy of treatment with glycosaminoglycans on experimental collagen-induced arthritis in rats. Arthritis Res Ther. 2003, 5: R122-131. 10.1186/ar748.View ArticlePubMedGoogle Scholar
- Petrella RJ: Hyaluronic acid for the treatment of knee osteoarthritis: long-term outcomes from a naturalistic primary care experience. Am J Phys Med Rehabil. 2005, 84: 278-283; quiz 284, 293. 10.1097/01.PHM.0000156899.18885.06.View ArticlePubMedGoogle Scholar
- Henderson EB, Smith EC, Pegley F, Blake DR: Intra-articular injections of 750 kD hyaluronan in the treatment of osteoarthritis: a randomised single centre double-blind placebo-controlled trial of 91 patients demonstrating lack of efficacy. Ann Rheum Dis. 1994, 53: 529-534. 10.1136/ard.53.8.529.View ArticlePubMedGoogle Scholar
- Puttick MP, Wade JP, Chalmers A, Connell DG, Rangno KK: Acute local reactions after intraarticular hylan for osteoarthritis of the knee. J Rheumatol. 1995, 22: 1311-1314.PubMedGoogle Scholar
- Hamburger MI, Lakhanpal S, Mooar PA, Oster D: Intra-articular hyaluronans: a review of product-specific safety profiles. Semin Arthritis Rheum. 2003, 32: 296-309. 10.1053/sarh.2002.50008.View ArticlePubMedGoogle Scholar
- Balazs EA: Analgesic effect of elastoviscous hyaluronan solutions and the treatment of arthritic pain. Cells Tissues Organs. 2003, 174: 49-62. 10.1159/000070574.View ArticlePubMedGoogle Scholar
- Aihara S, Murakami N, Ishii R, Kariya K, Azuma Y, Hamada K, Umemoto J, Maeda S: Effects of sodium hyaluronate on the nociceptive response of rats with experimentally induced arthritis. Nippon Yakurigaku Zasshi. 1992, 100: 359-365. 10.1254/fpj.100.359.View ArticlePubMedGoogle Scholar
- Pozo MA, Balazs EA, Belmonte C: Reduction of sensory responses to passive movements of inflamed knee joints by hylan, a hyaluronan derivative. Exp Brain Res. 1997, 116: 3-9. 10.1007/PL00005742.View ArticlePubMedGoogle Scholar
- Gomis A, Pawlak M, Balazs EA, Schmidt RF, Belmonte C: Effects of different molecular weight elastoviscous hyaluronan solutions on articular nociceptive afferents. Arthritis Rheum. 2004, 50: 314-326. 10.1002/art.11421.View ArticlePubMedGoogle Scholar
- Hashizume M, Koike N, Yoshida H, Suzuki M, Mihara M: High molecular weight hyaluronic acid relieved joint pain and prevented the progression of cartilage degeneration in a rabbit osteoarthritis model after onset of arthritis. Mod Rheumatol. 2010, 20: 432-438. 10.1007/s10165-010-0299-1.View ArticlePubMedGoogle Scholar
- Ozkan FU, Ozkan K, Ramadan S, Guven Z: Chondroprotective effect of N-acetylglucosamine and hyaluronate in early stages of osteoarthritis-an experimental study in rabbits. Bull NYU Hosp Jt Dis. 2009, 67: 352-357.PubMedGoogle Scholar
- Roth A, Mollenhauer J, Wagner A, Fuhrmann R, Straub A, Venbrocks RA, Petrow P, Bräuer R, Schubert H, Ozegowski J, Peschel G, Müller PJ, Kinne RW: Intra-articular injections of high-molecular-weight hyaluronic acid have biphasic effects on joint inflammation and destruction in rat antigen-induced arthritis. Arthritis Res Ther. 2005, 7: R677-686. 10.1186/ar1725.View ArticlePubMedGoogle Scholar
- Tung JT, Venta PJ, Caron JP: Inducible nitric oxide expression in equine articular chondrocytes: effects of antiinflammatory compounds. Osteoarthritis Cartilage. 2002, 10: 5-12. 10.1053/joca.2001.0476.View ArticlePubMedGoogle Scholar
- Takahashi K, Hashimoto S, Kubo T, Hirasawa Y, Lotz M, Amiel D: Hyaluronan suppressed nitric oxide production in the meniscus and synovium of rabbit osteoarthritis model. J Orthop Res. 2001, 19: 500-503. 10.1016/S0736-0266(00)90024-X.View ArticlePubMedGoogle Scholar
- Lee YT, Shao HJ, Wang JH, Liu HC, Hou SM, Young TH: Hyaluronic acid modulates gene expression of connective tissue growth factor (CTGF), transforming growth factor-beta1 (TGF-beta1), and vascular endothelial growth factor (VEGF) in human fibroblast-like synovial cells from advanced-stage osteoarthritis in vitro. J Orthop Res. 2010, 28: 492-496.PubMedGoogle Scholar
- Waddell DD, Kolomytkin OV, Dunn S, Marino AA: Hyaluronan suppresses IL-1beta-induced metalloproteinase activity from synovial tissue. Clin Orthop Relat Res. 2007, 465: 241-248.PubMedGoogle Scholar
- Gaber T, Dziurla R, Tripmacher R, Burmester GR, Buttgereit F: Hypoxia inducible factor (HIF) in rheumatology: low O2! See what HIF can do!. Ann Rheum Dis. 2005, 64: 971-980. 10.1136/ard.2004.031641.View ArticlePubMedGoogle Scholar
- Muz B, Khan MN, Kiriakidis S, Paleolog EM: Hypoxia. The role of hypoxia and HIF-dependent signalling events in rheumatoid arthritis. Arthritis Res Ther. 2009, 11: 201-10.1186/ar2568.View ArticlePubMedGoogle Scholar
- Issekutz AC, Sapru K: Modulation of adjuvant arthritis in the rat by 2-methoxyestradiol: an effect independent of an anti-angiogenic action. Int Immunopharmacol. 2008, 8: 708-716. 10.1016/j.intimp.2008.01.016.View ArticlePubMedGoogle Scholar
- Westra J, Brouwer E, van Roosmalen IA, Doornbos-van der Meer B, van Leeuwen MA, Posthumus MD, Kallenberg CG: Expression and regulation of HIF-1alpha in macrophages under inflammatory conditions; significant reduction of VEGF by CaMKII inhibitor. BMC Musculoskelet Disord. 2010, 11: 61-10.1186/1471-2474-11-61.View ArticlePubMedGoogle Scholar
- Rice JW, Veal JM, Fadden RP, Barabasz AF, Partridge JM, Barta TE, Dubois LG, Huang KH, Mabbett SR, Silinski MA, Steed PM, Hall SE: Small molecule inhibitors of Hsp90 potently affect inflammatory disease pathways and exhibit activity in models of rheumatoid arthritis. Arthritis Rheum. 2008, 58: 3765-3775. 10.1002/art.24047.View ArticlePubMedGoogle Scholar
This article is published under license to BioMed Central Ltd. This is an open access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.